What is the current stock price of Paratek Pharmaceuticals, Inc. (PRTK)?

As of the latest market data, Paratek Pharmaceuticals, Inc. (PRTK) is trading at $2.23. The stock has seen a gain of 1.83% today.

Does Paratek Pharmaceuticals, Inc. (PRTK) pay a dividend?

Based on current data, Paratek Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Paratek Pharmaceuticals, Inc.?

The current market capitalization of Paratek Pharmaceuticals, Inc. (PRTK) is approximately unavailable.

PRTK

Paratek Pharmaceuticals, Inc.·Healthcare

2.23

1.827%(+0.04)

Market Closed

Last Updated: — ET

52W L: $1.2952W H: $3.65

PRTK NEWS

globenewswire.com

Mar 18

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

Transaction adds TYMLOS ® to portfolio alongside NUZYRA ® and XHANCE ® and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on high-need, targeted therapeutic areas, today announced the completion of its combination with Radius Health, Inc., adding the osteoporosis therapy TYMLOS® (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines.

globenewswire.com

Feb 24

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

KING OF PRUSSIA, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers that address public health threats and important unmet medical needs, today announced positive top-line results in two important animal studies supporting the Animal Rule Development program for the Treatment of Pulmonary Anthrax. Specifically, a dose range-finding therapeutic efficacy study of NUZYRA (omadacycline) in a non-human primate (NHP) model of inhalation anthrax and a pivotal therapeutic efficacy study in a rabbit model of inhalation anthrax. The NHP study data were presented previously in a poster (ESCMID Global 2025, Vienna, Austria). The pivotal rabbit study data will be presented at a conference in Spring 2026. Anthrax is an infectious disease caused by gram-positive, rod-shaped, spore-forming bacteria (Bacillus anthracis) that can lead to severe illness and death.

Company Profile

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

268

IPO Date

2009-02-03

Beta

1.70

Websiteparatekpharma.com↗